Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EmbraceRX vs Trillium Meds

EmbraceRX
Graded #363

Lower grade

vs+10.800000000000004
Trillium Meds
Graded #124

Higher grade

The verdict

Trillium Meds takes it — 69.4/100 to 58.6/100.

Trillium Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Trillium Meds is a small, owner-operated telehealth platform based in Portland, OR that connects patients with independent licensed providers and FDA-registered compounding pharmacies for compounded…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrillium Meds +25
45
70
Dose & formulationTrillium Meds +8
56
64
Clinical oversightTrillium Meds +8
76
84
Labs & monitoringTrillium Meds +23
52
75
FulfillmentTrillium Meds +6
73
79
Contract termsEmbraceRX +35
55
20
EmbraceRX · left barTrillium Meds · right bar

The numbers

MetricEmbraceRXTrillium Meds
WeighScore58.6/10069.4/100
GradeCC
Scorecard rank#363#124
SemaglutideNot disclosed$119/mo (3-month plan, compounded)
TirzepatideNot disclosed$199/mo (3-month plan, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
EmbraceRX

Graded #363 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)
Trillium Meds

Graded #124 · C

Strengths

  • LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
  • All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
  • Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
  • Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
  • Klarna and Affirm financing available; pause anytime with no long-term commitment required

Where it loses points

  • No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
  • Small single-operator platform may limit capacity and support consistency as patient volume grows
  • Compounded medications are not FDA-approved; newer platform with limited long-term public track record
  • Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
  • No live video consult disclosed; async intake-form-based provider review by external licensed provider network

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard